VYNE Therapeutics Inc.

VYNE

US92941V3087

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
1.84 ^USD	+0.55%		-6.60%	-21.03%

07-01	VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Index	CI
07-01	VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Index	CI

VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Value Index

July 30, 2024

Latest news about VYNE Therapeutics Inc.

VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Index	06-30	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Index	06-30	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell Microcap Value Index	06-30	CI
VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Value Index	06-30	CI
Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer	06-24	CI
Arvinas, Inc. Appoints Andrew Saik as Treasurer	06-24	CI
Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202	06-13	CI
Top Premarket Gainers	06-07	MT
VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201	06-05	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	05-09	MT
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	05-06	MT
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	05-06	CI
Transcript : VYNE Therapeutics Inc. - Special Call	04-04
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	02-29	MT
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	01-10	CI
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors	01-03	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	11-13	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Transcript : VYNE Therapeutics Inc. - Special Call	11-09
VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors	10-31	CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	30/10/23	MT
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday	30/10/23	MT

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Sector

Pharmaceuticals

Calendar

08/07/2024 - Leerink Partners Therapeutics I&I and Metabolism Forum

More about the company

Income Statement Evolution

More financial data

Ratings for VYNE Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.84 USD

Average target price

5.583 USD

Spread / Average Target

+203.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VYNE THERAPEUTICS INC.	-21.03%	26.73M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals